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CHAPTER I 
 
 
INTRODUCTION 
 
 Osteoporosis is a serious health concern that has important implications for an 
individual’s quality of life. The disease is defined by low bone mass coupled with deterioration of 
bone that results in an increased risk for fracture [1]. The 2007 Report of the U.S Surgeon 
General estimates 35 million women and 17 million men in the US “at risk for osteoporosis”[2]. 
Furthermore, it is projected that by 2020,  50% of women aged 50 and older will experience an 
osteoporotic fracture in their lifetime [2]. Osteoporotic fractures occur with the highest frequency 
in the hip, vertebrae, and distal forearm [3-5]. Recently, Kannegaard et al observed an increase in 
the mortality of elderly men in the year following a hip fracture, a phenomenon that both 
demonstrates the severity of the disease and dispels the myth that osteoporosis is a gender 
specific disease [6]. Another common misconception regarding osteoporosis is that it is generally 
thought of as a disease that only affects older individuals. In fact, risk factors, contributing to 
osteoporosis begin during an individual’s youth at a time associated with the accretion of peak 
bone mass. Thus, the accrual of peak bone mass is a critical risk factor in the development of 
osteoporosis [7, 8].
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 Peak bone mass is determined by factors including weight bearing activities, adequate 
nutrient intake, and genetics [9-11]. Peak bone mass is acquired during adolescent years of rapid 
growth, roughly between the ages of 11 and 18 years of age, although it differs for each 
individual [12]. Moreover, both nutrition and weight-bearing exercise are two factors that appear 
to be protective against the development of osteoporosis [11]. Although calcium and vitamin D 
have received most of the attention in regards to nutrients involved in bone metabolism, other 
nutrients such as phosphorous, copper, and vitamin K are thought to play a role in maintaining 
optimal bone health [9, 11]. Additionally, iron has been recently identified as potentially having a 
role in bone metabolism [13-16].  
 Iron is an essential trace mineral, playing a vital role in metabolic pathways and 
possessing the critical function of oxygen transport throughout the body. With respect to bone 
metabolism, iron is involved in crucial reactions such as the action of prolyl hydroxylase on 
collagen maturation, where it is required as a cofactor to catalyze collagen cross-linking, a crucial 
step in the development of the skeletal system [17]. Iron also plays a vital role in cell 
proliferation, neurotransmitter biosynthesis, and energy production; thus, iron demands are 
increased during periods of growth to support cellular growth and proliferation [3]. However, the 
increased requirements place children at heightened risk of iron deficiency, which is currently the 
most common nutrient deficiency worldwide and affects approximately two billion individuals 
[18, 19]. In children, this deficiency can lead to serious impairment in cognition and growth, yet 
even in the US, approximately 9% of children under the age of 3 years old are reported as iron 
deficient [3, 20].  Importantly, women of childbearing age, approximately 12-49 years old, also 
exhibit an increased risk of developing iron deficiency due to a combination of menstruation and 
lower dietary intake. The wide range of ages at risk for an iron deficit is troubling, particularly in 
females, and can quickly lead to resultant health complications.   
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 Clinically, anemia is defined somewhat vaguely as a low level of hemoglobin caused by 
several dietary deficiencies including iron, folate, or vitamin B12 [3]. Thus, hematological 
parameters other than hemoglobin must also be considered in determining the cause of the 
anemia, including hematocrit, mean cell volume, serum iron, total iron binding capacity, ferritin, 
transferrin receptor, and transferrin saturation [3, 21, 22]. The estimated prevalence of iron 
deficiency anemia in the United States is between 9 and 16%, as reported by NHANES 1999-
2000; the target of Healthy People 2010, a governmental program geared towards improving the 
nation’s health, was to reduce the prevalence of iron deficiency in non-pregnant females aged 12-
49 from 11 to 7% [4, 23]. However, nearly three fourths of this population are documented as not 
meeting their nutritional requirement for iron [24]. This widespread inadequate intake paired with 
menstruation is likely the reason that this goal was not met by 2010, and is a current objective of 
Healthy People 2020 [25]. Although iron deficiency anemia remains a relatively common 
diagnosis in women, it can be easily treated or prevented in most cases through increasing dietary 
intake of iron [22]. Symptoms of iron deficiency include fatigue, decreased work capacity, 
dizziness, cardiomegaly, and in extreme cases, heart failure [3]. Although iron deficiency can 
occur in either gender, young women are more likely to be affected due to lower body stores of 
iron, menstruation, and an insufficient dietary intake of iron [3]. Despite symptoms and 
complications of severe iron deficiency being well characterized, relatively little is known about 
the long term risks of alterations in iron metabolism (e.g., iron deficiency), particularly during 
periods of growth.  
 Recent studies have demonstrated an intriguing connection between iron deficiency and 
negative alterations in bone mineral density (BMD), leading to the speculation that iron indeed 
plays a critical role in the regulation of normal bone metabolism [13-15, 26]. Interestingly, both 
iron deficiency and iron overload have been demonstrated to negatively affect skeletal health, and 
are associated with a decreased BMD in animal models [13-16]. In animal models of iron 
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deficiency, the BMD of the femur, tibia, and spine was decreased. Further, both bone formation 
and resorption are decreased in a weanling rat model of iron deficiency [13-15]. Consistent with 
these observations of alterations in bone metabolism with alterations in iron metabolism, female 
army recruits with iron deficiency anemia exhibit an increased risk of developing stress fractures 
[27]. As a result of these recent observations linking iron status and osteoporosis, a more focused 
examination of the mechanisms contributing to iron-depended alterations in bone metabolism is 
warranted.  
 Thus, in this study, our objective was to explore the effects of dietary iron deficiency on 
bone mineral density and bone microarchitecture in the tibia and spine from an animal model of 
iron deficiency. Additionally, we aimed to examine iron’s cellular function in the regulation of 
osteoclastic and osteoblastic differentiation using specimens from animals fed an iron restricted 
diet. Our central hypothesis was that iron deficiency during a period of rapid growth would 
negatively affect bone mineral density, bone microarchitecture, and the expression of genes 
related to osteogenesis.  
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
 
Osteoporosis 
 Osteoporosis is one the most common health concerns of older women and men 
worldwide. The World Health Organization (WHO) reports an estimated 1.66 million 
osteoporotic hip fractures annually, and this number is expected to quadruple in size by 2050 
[28]. Osteoporosis is characterized  by low bone mass coupled with deterioration of bone tissue 
that ultimately leads to porous bones that are at greater risk for fracture [1]. Osteopenia is not 
considered a disease, but rather a condition of low bone mass that puts the individual at greater 
risk for the development of osteoporosis [3]. A diagnosis of osteoporosis indicates that an 
individual’s bone mineral density (BMD) is more than 2.5 standard deviations below the BMD of 
20-29 year old females (the standard reference group), whereas a diagnosis of osteopenia 
indicates a BMD between 1 and 2.5 SD below the standard reference group [3]. These diagnoses 
correlate with an approximately 60% and 30% increased risk of lifetime fracture as a result of 
osteoporosis and osteopenia, respectively [28]. A fracture is defined as a break in the bone, and 
occurs most frequently in young children and in older adults [28]. Stress fractures are unique in 
the sense that rather than an actual break, the bone undergoes a series of microscopic fissures that 
do not damage adjacent soft tissue [29].  Stress fractures are commonly the result of overuse
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 injuries usually associated with exercise, though other causes of stress fractures may include 
conditions that interrupt normal bone modeling [7, 29]. 
Bone Composition 
 Bones are comprised a variety of tissues that work together to form the structural support 
for the human body and provide assistance in biomechanical movement and mineral storage. 
Additionally, the bone marrow cavity within the bone contains pluripotent stem cells capable of 
differentiating into mesenchymal, myeloid, or hematopoietic precursor cells [29]. The bone 
matrix, or osseuous tissue, is comprised of water, collagen fibers, and crystallized mineral salts 
including hydroxyapatite. Mineral salts including magnesium hydroxide, fluoride, and sulfate are 
deposited in the collagen matrix of the bone formed from prolyl hydroxylase catalyzed 
crosslinking of propeptide collagen fibrils [7, 30]. This matrix then undergoes calcification that 
results in bone formation [7]. Bones can be divided into two main categories: axial bone and 
appendicular bone. Axial bones function as the skeletal framework, and can be found in areas 
such as the skull, ribs, and vertebral column. Appendicular bones include those of the limbs, 
extremities, hips, and the scapula, and are characterized as supporting elements which connect to 
muscles, blood vessels, and axial bones [29]. Bones can also be divided or categorized according 
to their morphology. Examples include long bones (femurs and tibias), short bones (wrist and 
carpal bones), flat bones (cranial bones), irregular bones (vertebrae and calcaneus) and sesamoid 
bones (patellae). All of these types of bones vary in their tissue composition, which is either 
cortical or trabecular. Cortical tissue is compact and comprised of osteons (or haversian systems) 
that undergo continuous remodeling and form the external protective layer of bones. Trabecular 
tissue, or spongiosa, is composed of columns and struts of calcified matrix that add support and 
structure to the bone. Trabecular tissue  is found lining the cortical tissue long bones, the iliac 
crest, wrists, scapulas, and vertebrae [31]. The metaphyseal region of long bones is also 
trabecular-rich and a highly metabolic region. Importantly, trabecular tissue is found juxtaposed 
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to the bone marrow that flows through the medullary cavity of the bone. About 80% of the 
skeleton is made up of cortical bone tissue, and the remaining 20% is composed of trabecular 
bone tissue.  
Cellular Bone Modeling 
 Calcified skeletal tissue is constantly undergoing a remodeling process that involves the 
regulated resorption and remineralization of bone. The cycle of remodeling occurs throughout the 
lifespan and represents a critical process through which new bone is formed. Bone turnover is 
generally a delicate balance between bone formation and bone resorption. However, during 
childhood and adolescent growth, this balance is favored in the direction of bone formation to 
support the development and growth of the skeleton. Thus, for the scope of this study, we were 
acutely interested in bone modeling as opposed to bone remodeling. However, to understand 
where iron may play a role in the modeling process, it is imperative to understand the pathways 
and stimulators for both bone formation and resorption. Bone turnover is dependent upon the 
activity of bone forming cells (i.e., osteoblasts) and bone resorbing cells (i.e., osteoclasts). 
Osteoblasts are derived from mesenchymal stem cells (MSC) present in the bone marrow, and are 
responsible for secreting collagen fibers required for bone mineralization. In contrast to 
osteoblasts, osteoclasts are derived from hematopoietic stem cells (HSC) in the bone marrow, and 
their primary role is to counteract the actions of osteoblasts. The transcription of MSCs into 
osteoblasts and HSCs into osteoclasts is the result of complex signaling pathways and may 
function as key regulatory branch points for managing the balance between bone resorption and 
formation. 
Regulatory Mechanisms Controlling Osteoblastogenesis 
 Pluripotent mesenchymal stem cells (MSC) possess the potential to differentiate into 
chondryocytes, adipocytes, and osteoblasts through the induction of a variety of transcription 
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factors. For MSCs to be driven towards osteoblastic lineage, proteins such as β-catenin, bone 
morphegentic proteins -2, -3, and -4 (BMPs), transforming growth factor beta (TGFβ), and 
parathyroid hormone (PTH) must be present [32]. Signaling pathways associated with these 
proteins induce transcription of downstream regulators that are critical for osteoblasts function. 
Bone morphogenetic proteins are a class of proteins which are essential in the embryonic 
development of the skeletal system, but are also acutely involved in bone modeling throughout 
the lifetime. In particular, the cytokine BMP-2 has been recognized as stimulating osteoblastic 
activity though the activation of Smad signaling and the subsequent expression of runt-related 
transcription factor 2 (Runx2), a key factor in osteoblastogenesis [33].  
 Transcriptional regulators involved in the differentiation and maturation of osteoblasts 
include the transcription factors runt-related transcription factor (Runx2), osterix (OSX/SP7), and 
β-catenin. In mammals, activation of the Wnt/β-catenin canonical pathway promotes an increase 
in Runx2 gene transcription, a key step in osteoblastic differentiation [34, 35]. Similarly, BMPs 
and TGFβ stimulate receptor-activated Smad proteins (-1,-5,-8 and -2, -3, respectively) that 
promote transcription of Runx2 mRNA [36, 37]. Runx2 is considered a “master regulator” in the 
differentiation and maturation of osteoblasts due to its role in promoting the expression of osterix 
and binding to the activating transcription factor 4 (ATF4), which are both proteins involved in 
osteoblast differentiation [36, 37]. As described above, Runx2 is regulated by several classes of 
proteins, including BMPs and Wnt, which are antecedently regulated by the Hedgehog (Hh) 
family of proteins [36]. Interactions between Runx2 and ATF4 (activating transcription factor 4) 
promotes the transcription of osteocalcin, which is currently thought to play a role as the turning 
point between bone formation and bone resorption [7]. Runx2 also serves as a middleman of sorts 
for the regulation of osterix, a zinc finger transcription factor, by BMP2, which then induces 
expression of gene targets such as bone sialoprotein (BSP) and osteocalcin (OC) [36, 38]. Bone 
sialoprotein is one of the better characterized proteins of bone, functioning to bind and nucleate 
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hydroxyapatite and calcium in the process of forming new bone matrix [39]. Other important 
proteins induced by Runx2 transcription that are integral to osteoblasts function include bone 
matrix proteins such as osteopontin (OPN), a non-collagenous protein which covalently binds 
fibronectin in the bone matrix, osteonectin (ON), which binds calcium, hydroxyapatatite, and 
collagen, and  alkaline phosphatase (ALP), a glycoprotein which carries calcium and also serves 
to hydrolyze inhibitors of mineral deposition in the matrix [7]. Collagen type 1 (COL1A1), the 
most abundant type of collagen in the bone, is regulated by a variety of factors such as TGFβ, 
Smad proteins -2 and -3, insulin like growth factor I (IGF1), tumor necrosis factor α (TNFα), 
parathyroid hormone (PTH), and vitamin D [7]. Collagen proteins are essential in supporting the 
mineralization of the extracellular matrix, and must be hydroxylated in order to facilitate the 
cross-linking of collagen polypeptides to form the structural support of bone [7]. The iron-
dependent enzyme responsible for promoting collagen cross-linking and bone formation is prolyl 
hydroxylase [30].  
 Eventually, osteoblasts are trapped inside this new calcified matrix and termed 
osteocytes. Osteocytes are dendritic cells that are in contact with cells on the bone surface, other 
osteocytes, and importantly, with the bone marrow within the medullary cavity [40]. It is thought 
that osteocytes function to maintain the balance of bone resorption and formation, evidenced by 
the fact that osteocytes not only support osteoclastic activity but are also instrumental in 
stimulating MSC differentiation into osteoblasts [40-42].  Thus, it is postulated that osteocytes act 
as signaling cells. 
Transcriptional Regulation of Osteoclasts 
 In contrast to osteoblasts, osteoclasts are derived from HSCs [43]. The pathway resulting 
in the differentiation of HSCs into mature osteoclasts is initiated by the activation of NF-κB 
through the binding of receptor activator of NF-κB (RANK) to its ligand, RANKL [44, 45]. The 
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binding of membrane-bound RANK by RANKL can be stimulated by parathyroid hormone, 
prostaglandin E2, tumor necrosis factor alpha, or 1,25-dihydroxyvitamin D3, all of which have a 
role in the commitment of HSC towards osteoclastic lineage [32]. Once bound, the RANK-
RANKL complex activates a signaling pathway that evokes factors such as nuclear factor kappa 
B (NF-κB), TNF-receptor associated factors (TRAFs), and mitogen activated protein kinases 
(MAPKs) [32]. TRAF6 is critically involved in cytoskeleton organization of osteoclasts; without 
the activation of TRAF6 by RANKL-RANK, osteoclasts are unable to form the ruffled border 
that is integral for the resorptive function of osteoclasts [46]. MAPKs are critical for the 
regulation for activator protein-1 (AP1) family members such as JUN (c-Jun, JunB, JunD) and 
FOS (c-Fos, FosB, Fra-1) proteins that heterodimerize with one another to form transcriptionally 
active complexes, which in turn regulate the expression of genes involved in osteoclastogenesis 
[47]. In particular, c-Fos activates nuclear factor of activated T-cells (NFATc1) through a 
calcineurin dependent mechanism [48]. Together, RANKL and NFATc1 induce the terminal 
differentiation of bone marrow macrophages to osteoclastic lineage [48]. NFATc1 then induces 
the expression of genes involved in osteoclasts function, such as cathepsin K (CTSK), calcitonin 
receptor (CtR), and tartrate resistant acid phosphatase (TRAP) [48]. CTSK is a proteinase 
involved in bone matrix degradation, and TRAP is a generator of reactive oxygen species which 
are capable of destroying collagen [7, 49]. 
Coordination of Osteoblast and Osteoclast Activation 
 Osteoblast differentiation and maturation is involved in the differentiation and activation 
of osteoclasts through the osteoblastic expression of RANKL and macrophage colony-stimulating 
factor (M-CSF) [7]. In addition, RANKL can also be secreted by activated T-cells which can also 
induce osteoclastogenesis, along with the hematopoietic growth factor M-CSF that is locally 
produced by activated macrophages [50, 51]. Through an as yet unknown mechanism, RANKL is 
translocated from the nucleus of osteoblasts to the cell surface, where it is then competent to bind 
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by the cysteine-rich domains within RANK, the RANKL receptor on the cell surface of 
osteoclastic progenitor cells [7]. This induces several signal transduction pathways that involve 
TRAF6, c-Jun N-terminal kinases (JNK), and extracellular signal-regulated kinases (ERK); in 
short, these cascades allow for the survival, differentiation, and activation of osteoclasts [32]. 
Colony-stimulating factor receptor 1 (c-Fms) is also found on the cell surface of osteoclasts, and 
binds M-CSF secreted by the osteoblasts. Binding of M-CSF to c-Fms induces a signaling 
cascade that results in promoting the differentiation of osteoclastic progenitors to mononuclear 
osteoclasts which can then fuse together to become mature, multinucleated osteoclasts. These 
mature osteoclasts become activated and express proteins that are absorbed in bone resorption 
including TRAP, fos-related antigen (FRA), calcitonin receptor (CalcR), and CTSK as previously 
described [7].  
Regulation of Bone Modeling: Hormonal and Nutrient Factors 
 The human skeleton undergoes constant turnover, in which osteoclasts and osteoblasts 
continually resorb old bone and form new. This is considered bone remodeling, and is regulated 
through both hormonal and nutritional factors. During periods of growth, bone formation at a 
much faster rate than resorption in order to promote bone growth, or bone modeling, which is the 
focus of this study [52]. However, having an understanding of the key factors involved in the 
regulation of the bone remodeling process is still an important aspect to consider for our 
purposes. These regulation factors include parathyroid hormone, calcitriol, estrogen, calcitonin, 
calcium, ergocalciferal/cholecalciferol (dietary vitamin D), vitamin K, and phosphate [52]. 
 PTH secreted by the parathyroid glands stimulates osteoclastic resorptive activity [53]. 
Under normal physiological conditions, PTH is released as serum calcium levels decline [3]. The 
PTH-induced activation of osteoclasts results in the release of calcium and phosphorus into 
circulation. Thus, PTH plays a critical role in the maintenance of calcium and phosphorous 
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homeostasis [7]. In contrast, calcitonin is released from the parafollicular cells of the thyroid 
gland in response to elevated serum calcium [7]. Calcitonin increases skeletal deposition of 
excess calcium by promoting the activation of osteoblasts by increasing β-catenin levels via 
Smad-3 [54]. Thus, PTH and calcitonin are counter-regulatory hormones responsible for 
maintaining proper serum calcium concentrations and work, at least in part, by regulating bone 
resorption and bone formation, respectively. The sex hormone estrogen functions in large part by 
preventing the synthesis of the cytokines that result in the release of PTH and subsequent 
activation of osteoclasts [7]. In accordance with the role of estrogen in regulating bone turnover, 
age dependent decrease in estrogen is associated with an increased risk for developing 
osteoporosis.  
 Because the skeleton represents the abundant storage site for calcium, the maintenance of 
calcium homeostasis is reliant upon the storage and release of calcium in bone tissue. In addition 
to the actions of PTH and calcitonin, serum calcium levels are regulated by the actions of 
calcitriol, the hormonal form of vitamin D (1,25(OH)2D3). Calcitriol is the ligand for the vitamin 
D receptor (VDR), a member of the nuclear hormone receptor superfamily [7]. The activation of 
VDR by 1,25(OH)2D3 results in the activation of osteoblasts to increase the synthesis of bone 
matrix proteins required for new bone formation by promoting bone mineralization. Dietary 
vitamin D is obtained in the form of either ergosterol, ergocalciferol, or cholecalciferol which can 
serve as precursors for the synthesis of 25(OH)D3. Vitamin D3 can also be synthesized 
cutaneously by the conversion of 7-dehydrocholesterol to cholecalciferol through ultraviolet (UV) 
radiation. A vitamin D deficiency may result in increased osteoclastic activity promoting bone 
resorption and eventual bone loss.  
 Vitamin D3 (cholecalciferol) undergoes hydroxylation in the liver through the action of 
25-hydroxylasse to form 25(OH)D3. In order to form active vitamin D (i.e., calcitriol or 
1,25(OH)2D3), 25(OH)D3 must be hydroxylated by 1α-hydroxylase, predominantly expressed in 
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the kidney. The activity of this 1α-hydroxylase is increased in response to elevated levels of PTH, 
low serum calcium, and low calcitriol. Therefore, under insufficient calcium condition, 1α-
hydroxylase is increased leading to the enhanced production of calcitriol. Calcitriol acts to 
increase calcium absorption in the intestine, calcium resorption in the kidney, and stimulate bone 
resorption. It is critical that individuals of all ages consume the recommended amounts of dietary 
vitamin D and calcium to maintain a healthy balance between bone resorption and formation. 
Both vitamin D and calcium are therefore essential in the accretion of peak bone mass. Through 
the stimulation of 1,25(OH)2D3  and PTH in addition to other cytokines, osteoblasts and activated 
T-cells are driven to secrete RANKL, and bone marrow stromal cells secrete M-CSF, ultimately 
resulting in osteoclastic differentiation, proliferation, and maturation [50, 51].  
Methods of Assessing Bone Density and Microarchitecture 
 Because the diagnosis of osteoporosis and osteopenia is dependent on the ability to 
determine BMD and BMC, in vivo methods are utilized that allow investigators to assess bone 
related parameters. Several methods of assessing bone strength, density, and composition exist, 
but the most widely used clinical method of assessing skeletal health is dual energy x-ray 
absorptiometry (DXA). Analysis using DXA provides critical information such as BMD, BMC, 
and bone mineral area (BMA). BMD is often used in the assessment of bone after development 
stops. BMC assesses the accumulation of bone and is often used before an individual stops 
growing. Clinically, DXA is a powerful tool used to determine the level of fracture risk based on 
BMD. If detected early, low BMD can be increased through dietary, pharmacological, and 
physical activity-based interventions.  
 Additionally, micro-computed tomography (µCT), can be used to determine and examine 
the three dimensional architecture of the bone through the use of x-ray data that reconstructs an 
image of bone in voxels within a selected region of interest (ROI) [55]. In trabecular tissue, the 
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reconstructed 3-dimensional image provides characteristics of the structural struts (or trabeculae) 
can be analyzed to determine trabecular thickness (TbTh), trabecular number (TbN), and 
trabecular spacing (TbSp), all of which are indicators of the strength and micro-architecture of 
bone. Bone volume fraction (BV/TV) is an important measure of the ratio between the bone 
volume and total volume, which is then used for the calculation of TbTh, TbN, and TbSp [55]. 
Connectivity density is calculated as a measure of the connectivity of the trabeculae  divided by 
the total volume of the ROI to account for the size, and is used to gain a better understanding of 
the bone density within a given area [55].  The structural model index (SMI) is an architectural 
index that was designed to help predict the strength of a bone using a scale from 0 to 3 [55, 56]. 
An SMI value closer to 3 indicates a more rod-like structure in trabecular bone structure and 
indicates that a lesser vertical force would be required to break the bone, whereas a SMI closer to 
0 indicates a more plate-like trabecular structure that requires more force to break [55]. Thus, an 
elevated SMI is associated with a higher risk of fracture [56].  
Cortical tissue analyzed by µCT is quite similar to trabecular tissue measurements, but 
there are some key differences in the analysis. From the volume of interest, cortical bone area and 
cortical thickness are determined, which takes into account the cortical volume, and number and 
thickness of slices measured [55]. The medullary area of the ROI is also measured by µCT, along 
with porosity, which predicts the volume of the porous (or void) space within the bone and the 
total volume of the bone [55, 57].  
Using the measurements from µCT, a Finite Element Analysis (FEA) can be performed 
on the selected bone. FEA analysis utilizes a computer simulated model to convert the voxels of 
the 3D µCT image into an image that is composed of eight node brick elements, which are 
incorporated into a grid, and are then used for mechanical assessment of the approximated 
strength of the bone [58]. FEA computes the estimated force that would result in a fracture of the 
specified bone by calculating the Von Mises stress value, which is the point at which the stressor 
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exceeds the strength of the bone; simply put, the Von Mises stress is an indicator of how much 
mechanical loading a bone can withstand before a fracture occurs [59]. 
Determinants of Peak Bone Mass 
 Acquiring peak bone mass is the single most important factor in determining the risk of 
osteoporosis [11]. Peak bone mass is affected mainly by nutrition habits, exercise, along with 
genetics [11]. Following a nutritious diet is beneficial in the prevention of chronic disease, and is 
a key factor in osteoporosis prevention. It is important for children and adolescents to consume 
sufficient quantities of dietary calcium and vitamin D, as peak bone mass is attained a short time 
after an individual stops growing. Genetics also play a role, as a small bone frame is a risk factor 
for osteoporosis [5]. However, individuals with small frames can practice preventative measures 
such as adequate nutrition and weight bearing exercise to decrease their risk of osteoporosis. The 
exact age growth cessation is different for each individual, which is why it is so critical to 
optimize nutrition and participate in weight bearing activities regularly to maximize peak bone 
mass. Unfortunately, it is during this period of growth that adolescents, and in particular females, 
are at risk of nutrient deficiencies that may contribute to increasing risk for the development of 
chronic disease much later in life. One of the most common nutrients for which a deficiency may 
develop in the absence of adequate dietary intake is iron. In particular, iron disproportionately 
affects adolescent females and may impair an individual’s ability to attain peak bone mass [4, 9].  
Iron: An Essential Nutrient 
 Iron is the most abundant trace mineral in the body, and is required for processes such as 
cell proliferation, neurotransmitter biosynthesis, and the metabolism of both macro- and 
micronutrients [3]. However, iron is potentially toxic, as free ferrous iron molecules readily 
participate in oxidation reactions such as the Fenton reaction, resulting in reactive oxygen species 
(ROS) that pose a risk to cell membranes throughout the body [60]. Thus, to prevent the 
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circulation of free ferrous iron molecules, most of the iron in the body is protein bound. Several 
classes of protein-bound iron exist, which participate in a variety of functions; these including 
heme proteins, transport proteins, iron-sulfur cluster enzymes, and enzymes containing single- or 
di-iron catalytic centers.  
 Hemoproteins contain iron as part of the heme moiety and include proteins such as 
hemoglobin, myoglobin, and neuroglobin. Both hemoglobin and myoglobin serve to transfer 
oxygen throughout body tissues and muscle, respectively. Neuroglobin serves the central nervous 
system by supplying the brain with adequate quantities of oxygen [61]. Cytochrome proteins 
contain heme as a functional group and essential for facilitating the transfer of electrons and 
function in diverse processes such as cellular respiration and xenobiotic metabolism. The serum 
glycoprotein transferrin binds ferric iron and is required for the inter-organ transport of iron. Iron-
sulfur (Fe-S) cluster enzymes contain iron that can function as both an essential structural 
component of the protein as well as a part of the catalytic center. Examples of Fe-S cluster-
containing proteins include enzymes of the tricarboxylic acid cycle such as succinate 
dehydrogenase and mitochondrial aconitase.  
 Single iron-containing enzymes are involved in such reactions as DNA synthesis 
(ribonucleotide reductase) and for the cross-linking of collagen fibrils in connective tissue (prolyl 
hydroxylase) [62]. Iron-containing prolyl hydroxylases are also involved in the regulation of 
hypoxia inducible factors (HIF), which sense oxygen status in the body. When oxygen is 
sufficient, HIFs are transcriptionally repressed through ubiquitination by prolyl hydroxylation 
[63]. The wide scope of functions that require iron make iron one of the most important trace 
minerals. The potential role of iron’s involvement in bone formation and resorption only add to 
its importance in maintaining healthy body processes.  
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Dietary Iron Absorption 
 Dietary iron can be separated into two main categories, heme iron sources and non-heme 
iron sources – both of which are absorbed utilizing different pathways. To date, the absorption of 
non-heme iron is better understood than the absorption and transport of heme iron, but this is 
largely due to the lack of an identification of a specific heme iron transporter. Heme iron derived 
exclusively from animal sources is more efficiently absorbed than non-heme or inorganic iron 
[64]. Non-heme iron dietary iron is usually obtained from plant-based foods and considerably less 
bioavailable than heme iron [64]. 
 In the lumen of the small intestine and prior to uptake by the enterocyte, non-heme ferric 
(Fe3+) iron must be reduced to ferrous (Fe2+) iron by brush border ferrireductases such as 
duodenal cytochrome b (dCytB) [65]. Ferrous iron is then transported across the apical membrane 
by the divalent metal transporter-1 (DMT-1). DMT-1 is somewhat promiscuous for its substrates 
as it can transport other divalent metal cations in addition to iron; however, the KM for iron is 
higher than other metals  [66]. DMT-1 expression is up-regulated in response to iron deficiency 
or hypoxia, a condition caused by lack of oxygen in the body, in order to maximize duodenal iron 
absorption. Although heme iron transport is more efficient than non-heme iron transport, the 
proteins controlling heme iron transport across the apical membrane of the enterocytes remain 
poorly understood, but an energy-dependent membrane protein expressed only in the duodenum 
has been suggested to play a role [67].  
 Once inside the enterocytes, iron has three fates: storage, transport, or utilization. When 
body iron status is sufficient, it is stored as ferritin. However, when iron is needed, it is exported 
across the basolateral membrane and oxidized prior to loading onto transferrin for transport 
throughout the body to where it is needed [65].. Ferrous iron is transported across the basolateral 
membrane of the enterocytes by ferroportin. On the extracellular membrane, the membrane-
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bound multi-copper oxidase hephaestin oxidizes iron, allowing transferrin to bind the iron for 
transport to other tissues of the body [65]. Iron recycling is a tightly controlled process, where the 
amount of iron absorbed per day is roughly equal to the amount of iron that is excreted per day. 
The only mechanism for iron excretion is through enterocyte turnover (3-5 days). Thus, 
conditions that lead to an enhanced sloughing or loss of enterocytes may contribute to an 
impaired iron status. Because no specific mechanism exists for regulating iron excretion from the 
body, the primary point of regulation is through iron absorption which is dependent upon the rate 
of erythropoiesis and the abundance of body iron stores. Due to the relatively low bioavailability 
of iron from the diet and lack of a regulated excretory pathway, iron is efficiently conserved and 
recycled throughout the body. The absolute amount of iron absorbed on a daily basis is 
approximately equal to the amount of iron loss (about 1-2 mg iron/day in normal individuals) 
[68]. 
Iron Transport 
 Ferrous iron is transported across the basolateral membrane, and is oxidized by 
ceruluplasmin or hephaestin to ferric iron, which can be taken up by apo-transferrin (Tf), the 
primary iron transport protein in the serum. Apotransferrin binds two Fe3+ molecules (diferric 
holotransferrin). Holotransferrin transports iron to body tissues, including the liver, the primary 
storage site for iron. The iron uptake protein Transferrin Receptor (TfR), found on virtually all 
cell membranes, binds diferric holotransferrin with high affinity, and monoferric or apotransferrin 
with a much lower affinity, promoting the cellular uptake or iron. A second transferrin receptor 
(TfR-2) is present in the liver, but is expressed primarily in hepatocytes and is thought to play a 
role as an iron sensor [69]. TfR is critical in the regulation of iron homeostasis, as it functions in 
cellular iron uptake in almost all cells throughout the body [70]. Under iron restricted conditions, 
the stability of TfR mRNA is increased and promotes an enhanced uptake of TfR-bound iron. 
Conversely, TfR mRNA is less stable under iron-sufficient conditions. Mice with a TfR -/- 
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genotype exhibit symptoms of hemochromatosis due to the inhibition of iron uptake, furthering 
the importance of transferrin receptor expression as a means of regulating systemic iron balance 
[71].  
Iron Storage 
 Iron absorbed in excess of needs is stored in the macromolecular protein ferritin. Iron is 
stored only when circulating iron is sufficient to carry out normal body processes. Iron stores in 
men are typically much higher than in women and may contribute to the increased prevalence of 
iron deficiency anemia in women (12% compared to 2% in males) [3, 65]. Ferritin is a 
heteropolymeric protein containing varying compositions of two subunits, heavy or heart (H-
ferritin) and a light or liver (L-ferritin).  
Iron Utilization 
 Release of iron from the liver takes place under the regulation of hepcidin, along with the 
multi-copper oxidases hephaestin and ceruluplasmin. Hepcidin, a circulating peptide hormone 
synthesized and secreted primarily by hepatocytes in response to elevated iron stores, plays a 
major role in systemic iron homeostasis by negatively regulating the action of ferroportin [65]. 
Iron is released from enterocytes and storage sites (e.g., liver and macrophages of the 
reticuloendothelial system or RES) through ferroportin, and is subsequently oxidized to ferric 
iron by the multi-copper oxidases hephaestin (enterocytes) and ceruloplasmin (liver and RES) 
before being bound by transferrin. Once in circulation, the majority of iron is utilized to support 
bone marrow erythropoeisis requiring the formation of the iron-containing protein hemoglobin 
for the transport of oxygen. Hematopoiesis is a cycle that is entirely dependent of the Transferrin-
TfR cycle for iron acquisition and the formation of hemoglobin [68]. Iron is required for the 
synthesis of the erythroid-specific isoform of aminolevulinate synthase (eALAS) that is the rate-
limiting step in the heme biosynthetic pathway. Iron is then incorporated into protophorphyrin IX 
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in mitochondria during the final step of the heme biosynthetic pathway to form heme [65, 72]. 
Accordingly, in response to iron deficiency, hematopoietic cells exhibit the most marked signs of 
deficiency resulting in the production of microcytic and hypochromic red blood cells that have a 
defect in their  oxygen-carrying capacity [3]. A lack of adequate iron to support oxygen transport 
is responsible for symptoms of iron deficiency anemia – namely fatigue, lethargy, and a 
decreased work capacity.  
 Iron is also a critical factor in the tricarboxylic acid cycle (TCA) as a part of the enzyme 
aconitase. Aconitase is an iron-sulfur containing enzyme which interconverts citrate to isocitrate. 
Both cytosolic and mitochondrial aconitases, encoded by different genes, require a 4Fe-4S iron-
sulfur cluster for catalytic activity.  The cytosolic isoform of the TCA enzyme m-acon is a 
bifunctional protein existing in either an enzymatic form or as a cytosolic RNA binding protein. 
Iron deficiency promotes the loss of the 4Fe-4S cluster thereby decreasing enzymatic activity and 
increasing the RNA binding activity of the protein. Previous work has demonstrated that the flux 
of carbon skeletons through the mitochondrial TCA cycle may be decreased in response to iron 
deficiency, and could contribute to an acute accumulation of mitochondrial citrate [73].  
Regulation of Iron Homeostasis 
Iron homeostasis is maintained at both systemic and cellular levels. Iron is not only an 
essential nutrient, but is also potentially toxic due to its propensity to participate in the generation 
of ROS [74]. Because of this essential yet potentially toxic nature, iron must be scrupulously 
regulated to prevent both iron overload and iron deficiency. Within the last decade, the systemic 
iron regulator known as hepcidin was discovered and characterized, and has provided valuable 
information about the coordination of both systemic and cellular regulation of iron metabolism.  
 The peptide hormone hepcidin is released by hepatocytes in response to factors such as 
excess iron and inflammation [75].  Hepcidin functions as a direct regulator of iron release from 
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cells [75-77]. Under high iron conditions, or in response to inflammation, hepcidin is synthesized 
and released from hepatocytes and upon binding target cells represses iron release by binding to 
the iron export protein ferroportin and promoting its degradation [68]. Conversely, under low iron  
or hypoxic conditions, hepcidin expression and synthesis is decreased, thereby decreasing 
degradation and allowing ferroportin to function as an iron exporter [65]. Iron released from cells 
is then made available and transported to the bone marrow on transferrin to support 
erythropoiesis.  
 Recently, bone morphogenetic proteins (BMPs) have been identified as playing a role in 
iron regulation [78-81]. BMPs belong to the transforming growth factor beta (TGF-β) 
superfamily, and upon their discovery were originally thought to play a role solely in bone 
formation [78]. However, extensive investigation has shown that BMPs participate in numerous 
cell pathways such as Smad signaling, binding to extracellular matrices, and transmembrane 
serine/threonine kinase receptors [82]. BMPs are involved in signal transduction pathways, 
working through receptor-activated Smad proteins, Smad-1, -5, and -8 [79]. Once activated, the 
Smad proteins induce a signaling cascade that ultimately results in the expression, synthesis, and 
secretion of hepcidin from the liver [79]. Though BMP2, -4, and -6 are all expressed in the liver, 
BMP-6 has been identified as key in iron homeostasis regulation by enhancing hepatic expression 
of hepcidin in response to elevated iron stores [83].  BMP-6 itself is also regulated in an iron-
dependent manner through an unknown mechanism [80, 84]. 
 Systemic iron regulation is also dependent on the related multi-copper oxidases 
hephaestin and ceruluplasmin whose functions are critical for allowing iron exported by cells to 
bind the iron transport protein transferrin. Hephaestin is a membrane-bound multi-copper oxidase 
expressed primarily intestinal tissue that functions to oxidize ferrous iron transported by 
ferroportin to allow its binding to transferrin [85]. Ceruloplasmin, the soluble orthologue of 
hephaestin, is required for the oxidation of iron released from extra-intestinal tissues (e.g., 
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hepatocytes and RES cells). Both hephaestin and ceruluplasmin are essential for iron to be bound 
by transferrin in order to move iron from sites of uptake or storage (e.g., intestine or liver) to sites 
of utilization (e.g., bone marrow). Loss of hephaestin is responsible for the iron-deficient 
phenotype of the sex-linked anemia (sla) mouse characterized by normal iron uptake by the 
enterocytes but a severely impaired transfer of iron into the serum [86]. Loss or a defect in the 
synthesis of ceruluplasmin leads to a toxic accumulation of iron in the liver [87].  
 Whereas systemic iron homeostasis is regulated by the peptide hormone hepcidin, 
cellular iron homeostasis is coordinated post-transcriptionally by a family of cytosolic RNA 
binding proteins known as the Iron Regulatory Proteins (IRPs). IRPs bind to highly-conserved 
stem-loop structures termed iron responsive elements (IREs) present in either the 5’ untranslated 
region (UTR) or 3’ UTR within messenger RNA (mRNA) encoding proteins involved in iron 
uptake, storage, and utilization [74]. IRPs binding to IREs present in the 5’ UTR (e.g. , ferritin) 
are associated with translational repression whereas IRPs binding to IREs present in the 3’ UTR 
are associated with enhanced mRNA stability via protection of an endonucleolytic cleavage site 
(TfR1 and DMT-1) [74, 88]. There are two isoforms of IRP which are largely analogous to each 
other but are regulated via distinctly different mechanisms.  
 IRP-1 is a bifunctional protein existing either as the cytosolic isoform of the TCA cycle 
enzyme aconitase or as a cytosolic RNA binding protein.  The enzyme form of the protein 
contains a 4Fe-4S iron-sulfur cluster whereas the RNA binding form of the protein is devoid of 
cluster.  The so-called iron-sulfur cluster switch is what determines the form of the protein with 
the cell.  Under iron sufficient conditions, the assembly of the enzyme form is favored resulting in 
a diminution of RNA binding activity.  Conversely, under iron deficient conditions, the 4Fe-4S 
cluster is removed generating the high-affinity RNA binding form of the protein.  Due to steric 
hindrances, the enzyme form of the protein is incapable of exhibiting high-affinity RNA binding 
activity for cognate RNA targets [72]. In contrast for the Fe-S cluster switch controlling IRP1/c-
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acon activity, IRP2 activity is modulated largely through protein stability.  IRP2 cannot 
accommodate the formation of a 4Fe-4S iron sulfur cluster and as such does not exhibit any 
aconitase activity.  Instead, IRP2 protein is regulated by cellular iron status.  Under high iron 
conditions, IRP2 is degraded through proteosomal degredation [89, 90]. Under iron deficient 
conditions, IRP2 is stabilized and exhibits high-affinity RNA binding activity. Thus, the binding 
activities of both IRP1 and IRP2 is increased in response to a decrease in the labile cellular iron 
pool thereby allowing IRPs to regulate cellular iron  homeostasis to promote the uptake of iron 
via stabilization of TfR mRNA and a repression in the translation of the mRNA encoding the 
ferritin polypeptide[74].  
Iron Related Diseases 
 It is imperative that iron regulation is well maintained, as iron-related diseases are 
deleterious to health and likely have long term negative effects. Examples of iron-related diseases 
include thalassemias, hemochromatosis, anemia of chronic disease, and iron deficiency anemia 
[3].  
 The thalassemias are the result genetic abnormalities resulting in the reduced synthesis of 
hemoglobin due to the mutations in the genes encoding globin chains [3]. Numerous variations of 
thalassemia exist, but are generally classified into two main groups: alpha and beta thalassemias, 
which correspond to the specific globin chain (alpha or beta) that is improperly formed. Within 
the two groups are a series of different forms of thalassemias, all of which have a different 
pathophysiology [91, 92].Alpha−thalassemia (α-thalassemia) presents with microcytic, 
hypochromic anemia as seen in iron deficient anemia, but the causes of alpha thalassemia range 
from a complete lack of α-globin to a defective formation of the chain that causes a lethal form of 
hemolytic anemia [92]. The defective formation of the β-globin chain seen in β−thalassemia 
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requires regular transfusions of red blood cells. The requirements for frequent and regular 
transfusion enhances a patient’s  risk for developing iron overload [93]. 
 Generic Hemochromatosis (iron overload) can result from thalassemias, very high 
concentrations of iron in the diet, or from over-efficient iron absorption, stemming from genetic 
mutations in genes encoding iron-related proteins. Classical hereditary hemochromatosis, the 
most common cause of iron overload, results from a mutation in the HFE gene and is thought to 
primarily affect individuals of Northern European descent.  Other causes of genetic 
hemochromatosis are the result of mutations in the genes encodingTfR2, hemojuvelin (HFE2), 
ferroportin, and hepcidin (HAMP) [68]. Each type of hereditary hemochromatosis is linked with 
inappropriately low levels of hepcidin activity in the body which results in the dysregulation 
between iron stores and iron absorption from the gut [65].. The excess iron accumulation in 
hemochromatosis-related disorders is associated with an increased generation of ROS that is 
speculated to results in tissue damage leading to cirrhosis, cardiomyopathy, and diabetes [65]. 
Only in exceptionally rare cases is hemochromatosis caused by dietary overload. One of the only 
major documented cases of a dietary overload took place in Zimbabwe, where traditionally 
brewed beer was found to contain excess amounts of iron, due to the steel drums used for brewing 
[94].  
 Anemia of chronic disease is often observed in patients with autoimmune disorders, 
diseases of chronic inflammation, and chronic renal disease, but has a fundamentally different 
pathology than iron deficiency anemia caused by inadequate dietary intake.  In the anemia of 
chronic disease, or anemia of inflammation, chronic inflammation leads to the elevated levels of 
inflammatory cytokines (e.g., interleukin-6 and tumor necrosis factor alpha) that, independent of 
iron status, cause the expression, synthesis, and secretion of hepcidin [95] As a result of elevated 
hepcidin levels, iron homeostasis is disrupted in anemia of chronic disease through the impaired 
release of iron from cells of the RES[95]. . Thus, through the repression of iron release, there is 
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insufficient iron made available to the bone marrow to support heme biosynthesis and 
erythropoiesis[95]. Furthermore, independent of iron, inflammatory cytokines increase ferritin 
transcription promoting inappropriately high iron storage  [96]. Though a milder anemia, anemia 
of chronic disease often results in a poor prognosis for the patient as the body must compensate 
for the decrease in oxygen being supplied to the body during an already fragile state of health 
[95]. 
Iron deficiency anemia is the most common iron-related disorder, occurring with the 
most frequency in females between the ages of 12-49. It is generally the result of inadequate 
dietary intake and the relatively poor bioavailability of iron in foods. Anemia is diagnosed when 
hemoglobin and hematocrit levels fall below the normal range (120-160 g/L and 35%, 
respectively). To determine whether the anemia is iron related, serum ferritin, soluble TfR, serum 
iron, serum transferrin, and total iron-binding capacity maybe measured. In response to an 
impaired iron status, a series of events occur in an effort to maintain iron homeostasis. At the 
cellular level, IRP1 and IRP2 exhibit an increase in RNA binding activity for mRNAs containing 
IREs in either the 5’- or 3’-UTR encoding proteins involved in cellular iron uptake, storage, and 
utilization.  For example, mRNAs containing an IRE within their 5’-UTR including ferritin, m-
acon, and ferroportin are translationally repressed in response to an iron-deficient activation of 
IRP RNA binding activity.  In contrast, TfR mRNA is stabilized as a result of enhanced IRP RNA 
binding activity due to iron deficiency leading to an accumulation of the TfR transcript and an 
increased expression of membrane-associated TfR to facilitate iron uptake In this way, IRPs can 
be considered to function as global regulators of cellular iron metabolism and serve to coordinate 
interorgan iron transport, uptake, storage, and utilization. 
In response to iron deficiency anemia, hepcidin expression, synthesis, and secretion is 
inhibited, leading to the derepression of hepcidin-mediated ferroportin degradation thereby 
promoting iron release from available iron stores or iron uptake from the intestine[68]. If dietary 
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intake of iron remains insufficient to support requirements, or if intestinal absorption remains 
poor, body iron stores are depleted and the lack of iron is incapable of supporting heme 
biosynthesis and erythropoiesis. This decrease in hemoglobin formation and impaired 
erythropoiesis results in microcytic hypochromic erythrocytes with a profound decrease in 
oxygen carrying capacity. Although the condition is easily treated by iron supplementation if due 
to inadequate dietary intake it often goes undiagnosed and may contribute to cardiomyopathy and 
heart failure in prolonged and severe cases of deficiency   
Iron and Bone 
 Due to the critical roles of iron in cellular metabolism, alterations in iron status or a 
dysregulation of iron homeostasis may adversely affect normal cell function. The focus of this 
study was to characterize the impact of iron deficiency on cells involved in maintaining normal 
bone metabolism and physiology. For example, under normal conditions during differentiation 
and maturation, cellular needs for iron increase to promote cell division and proliferation.  This 
increase in needs is reflected by an increase in TfR expression to facilitate an enhanced capacity 
of iron uptake. In terms of bone, osteoblasts require  iron as a component of prolyl hydroxylases, 
which catalyze collagen cross-linking  by hydroxylating prolyl residues in peptide linkages within 
bone [62]. A protein essential for bone resorption by osteoclasts, tartrate-resistant acid 
phosphatase (TRAP) requires iron for enzymatic function [49]. Therefore, alterations in iron 
status may result in a dysregulation of bone turnover which may adversely affect bone strength, 
mass, density, and microarchitecture, potentially increasing the risk of fracture or long-term risk 
of developing osteoporosis. In fact, several studies have identified a strong possibility that iron is 
involved in bone metabolism [13-16, 26].  
 In a rat model of iron deficiency, femur bone mineral area, bone strength, and BMD were 
decreased in the absence of adequate dietary iron [14]. Even when compared to a calcium-
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restricted diet, animals receiving an iron deficient diet exhibited the lowest trabecular number 
(TbN) in the vertebrae [14]. More recently,  Katsumata et al found that TbN, BV/TV,  BMC, and 
BMD were all significantly lower in the femurs of iron deficient rats [15]. In fact, even a 
“moderate” level of iron restriction with 12 mg Fe/kg in female Long-Evan rats resulted in 
decreased cortical thickness at the femur midshaft and negatively affected bone strength [26]. 
Iron deficiency induced by treatment with a synthetic iron chelator in a cultured human fetal 
osteoblast cell line was associated with impaired mineralization, though collagen synthesis was 
unaffected [26]. The results of these animal and in vitro studies suggest that there is indeed a 
specific role for iron in regulating osteoblast function and activity. 
The extent to which an impaired iron status is associated with an increased risk of 
fracture or increased risk of developing osteoporosis is considerably less clear.  There are 
relatively few studies that have interrogated the relationship between iron status and optimal bone 
health, and the majority of these focused on genetic diseases of iron overload.  Somewhat 
surprisingly, low BMD is also exhibited in human subjects with hereditary hemochromatosis [16, 
97]. Roughly three quarters of patients with hereditary hemochromatosis are diagnosed with 
osteopenia, and roughly one third are osteoporotic [16]. Importantly, Valenti et al demonstrated 
that the incidence of osteoporosis was independent of hemochromatosis genotype among subjects 
[16]. This critical information suggests that the condition of iron overload is a more pertinent 
factor in development of osteoporosis rather than type of genetic mutation in observed in 
hemochromatosis. Suggested mechanisms to explain this phenomenon are that an excess of iron 
increases the rate of bone loss as a result of hemochromatosis related hypogonadism, or that 
excess iron is toxic to osteoblasts function and/or recruitment, therefore suppressing bone 
formation [16]. In one of the few human studies available that did not examine individuals with 
hereditary iron overload disorders, female army recruits with low iron levels exhibited a higher 
prevalence of stress fractures, although BMD was not analyzed [27]. To date, no concrete 
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mechanism has been determined to explain this phenomenon, but hypothesized mechanisms 
include a decrease in the activity of iron-dependent enzymes that  alter bone metabolism or 
through a decreased activity of heme-dependent enzymes required for the formation of the 
biologically active vitamin D metabolite 1,25(OH2) Vitamin D3 which could subsequently affect 
bone formation[14, 15].  
 This paradoxical relationship suggests that iron has an important role in maintaining a 
healthy balance between bone formation and resorption. Interestingly, the regulation of both iron 
metabolism and bone remodeling share common signaling pathways involving bone 
morphogenetic proteins. BMP6 was recently identified as playing a crucial role in maintaining 
iron homeostasis through regulation of hepcidin expression [78-81].  Hemojuvelin (HJV), a 
protein mutated in early onset hemochromatosis, is a co-receptor for BMPs, particularly BMP6, 
and induces phosphorylation of Smads 1/5/8 and subsequent binding with Smad4 [79, 80]. This 
complex is translocated to the nucleus, where it activates the hepcidin gene promoter HAMP [80]. 
Despite the recent advances in understanding the molecular mechanisms coordinating iron 
cellular and systemic iron homeostasis, relatively little is known about how an impaired iron 
status results in skeletal mineralization abnormalities.  Thus, the focus of the work presented 
herein was to examine potential mechanisms through which a dietary iron deficiency may 
contribute to a decreased BMD and microarchitectural alterations in bone.
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CHAPTER III 
 
 
METHODOLOGY 
 
Animal Model of Iron Deficiency 
 Thirty weanling 21-day old male Sprague Dawley rats were purchased through the 
Oklahoma State University Laboratory Animal Research Facility from Harlan Laboratories 
(Madison, WI). Animals were housed individually in wire-bottomed cages and kept on a 12 hour 
light: dark cycle (7 AM - 7 PM) in a temperature- and humidity-controlled room with ad libitum 
access to deionized distilled water. Previous studies have demonstrated that this weanling model 
of iron deficiency is effective at producing a profound iron deficiency [45]. Additionally, this 
model provides an opportunity to observe the extent to which iron deficiency during a period of 
significant growth is associated with changes in bone structure, microarchitecture, and BMD [9]. 
Previous work by our colleagues and others has demonstrated a significant decrease in BMD in 
response to both a moderate and severe iron deficiency [5-6]. Purified diets following the 
guidelines of the American Institute of Nutrition (AIN-93G) were purchased from Harlan-Teklad 
(Madison, WI) (Table 1). All animals received ad libitum access to the control diet (Harlan –
Teklad #TD 94095) for a one week acclimation period prior to starting the dietary treatments. 
After the acclimation period, rats were randomly assigned to one of the thr
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groups: (1) control (C, n=4) diet providing 40 mg Fe/kg diet (Harlan-Teklad #TD.94095), (2) iron 
deficient (ID, n=11) providing < 3 mg Fe/kg diet (Harlan-Teklad #TD.80396), or (3) pair fed (PF, 
n=12) a control diet to the level of intake as the ID group. Both the C and ID groups were 
provided ad libitum access to diets. Previous work has shown that animals consuming a severely 
restricted iron-deficient diet exhibit a significantly decreased intake, thereby necessitating the 
incorporation of the pair-fed treatment group [88, 98].  
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Formula Composition 
Diet Components AIN 93G  (g/kg) Diet Components Iron  Deficient (93G) 
(g/kg) 
Caseine 200  Caseine 200  
L-Cysteine 3  L-Cysteine 3  
Corn Starch 397.486  Corn Starch 397.486 
Maltodextrin 132  Maltodextrin 132  
Sucrose 100  Sucrose 100  
Soybean Oil 70  Soybean Oil 70  
Cellulose‡ 50    
Mineral Mix  35  Mineral Mix 35 
Vitamin Mix 10  Vitamin Mix 10 
Choline Bitartrate 2.5  Choline Bitartrate 2.5 
TBHQ, antioxidant 0.014 TBHQ (antioxidant) 0.014 
Macronutrient Composition 
 
Diet % CHO 
 
% Lipid % Protein 
AIN 93G 
(TD.94095) 
63.9 17.2 18.8 
Iron Deficient Diet 
(TD.80396) 
 (2-5 mg Fe/kg) 
65.6 16.4 18.0 
Table 1 Formula & Macronutrient composition of the diets used for the present study. 
‡Cellulose contains background iron and thus was excluded as a component of the iron deficient diet to ensure that iron 
was kept at a level of 2-5 mg Fe/kg diet.
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Assessment of Iron Deficiency 
 After 35 days of treatment, the animals were anesthetized with an intraperitoneal 
injection of 0.004 -0.005 mL/g BW ketamine/xylazine, (60 mg/mL ketamine, 6 mg/mL xylazine). 
Arterial blood was collected from the descending aorta and immediately placed into either an 
EDTA-coated tube (#364300, BD Vacutainer EDTA 4 mg, Franklin Lakes, NJ) or serum 
collection tube (#366703BD Vacutainer, Franklin Lakes, NJ). Whole blood collected into EDTA-
coated tubes was used for the analysis of a complete blood count, reticulocyte count, and 
hemoglobin and hematocrit (Antech Diagnostics, Irvine, CA). Blood collected into serum tubes 
was allowed to clot and then centrifuged at 1800 x g for 20 minutes at 4°C. 
 
Collection of Tissues 
 Tissues harvested include the liver, spleen, kidneys, heart, gastrocnemius, soleus, and 
brain. All tissues were snap frozen in liquid nitrogen. Prior to freezing, a small portion of the liver 
was excised and stored in 10 mL buffered formalin (#8BUFF-FORM10%, pH 6.8-7.2, Pharmco-
AAPER, Brookfield CT). Heart, liver, and total body weight were measured on the day of tissue 
collection. Spines from animals were excised and frozen at -20°C. Both tibias were excised, and 
following soft-tissue debridement were stored in buffered formalin. Both femurs were flushed 
with 6 mL ice-cold phosphate buffered solution (PBS) for bone marrow collection; one tibia was 
also flushed for bone marrow collection for protein analysis, while bone marrow collected from 
the other femur was used for RNA extraction. After the femurs were flushed they were frozen in 
liquid nitrogen for future analysis.  
 
Bone Mineral Density and Composition Analysis 
 Prior to exsanguination, each animal underwent a dual energy x-ray absorptiometry scan 
(DXA, Hologic QDR Series 4500) to assess whole-body bone mineral area, content, and density 
(BMA, BMC, and BMD, respectively). Following tissue collection, a tibia and the spine of each 
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animal were also scanned using DXA.  Specifically, the BMC and BMD of the Lumbar 4 and 5 
(L4/5) vertebrae were analyzed.  
 
Assessment of Bone Microarchitecture (µCT) 
 To examine alterations in bone microarchitecture, L4 vertebrae and tibias were scanned 
using micro-computed tomography (microCT, µCT 40 SCANCO Medical, Switzerland). Tibias 
were analyzed at both the proximal diaphysis and the mid-diaphysis at medium resolution (1024 x 
1024 pixels). At the proximal diaphysis, a 100 slices volume consisting of only secondary 
spongiosa was specified as the volume of interest (VOI) to analyze trabecular tissue. Within the 
VOI, bone volume per trabecular bone volume (BV/TV), trabecular number (TbN), thickness 
(TbTh), and separation (TbSp) were determined. From these measurements, both the structural 
model index (SMI) and connective density (ConnDens) of the specimen were computed. The 
mid-diaphysis of the tibia was examined as a measure of cortical bone, with 40 slices comprising 
the VOI. This midpoint of the bone was then analyzed for porosity, cortical area, and medullary 
area. The 4th lumbar (L4) vertebrae were scanned at medium resolution and VOI was determined 
to begin 10 slices distal to the break between primary and secondary spongiosa. For trabecular 
analysis of the vertebrae, each VOI comprised 120 slices, where BV/TV, TbN, TbTh, TbSp, SMI, 
and ConnDens were analyzed.  
 
Finite Element Analysis 
 Following µCT, the reconstructed images of the trabecular bone within the proximal 
tibial metaphysis and 4th lumbar vertebral body were further assessed using finite element 
analysis software (FE), where images are converted to a three dimensional representation of the 
VOI. A simulated model of the approximated bone is created using a system of nodes, allowing 
the model to be tested for size independent stiffness, the amount of total force the bone can 
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withstand, and Von Mises, a stress value that is calculated from mechanical tests and can predict 
the breaking point of materials [58, 59]. 
  
Total RNA Extraction  
 To assess the alterations seen in iron deficient animal specimens at a cellular level, 
femurs were debrided of soft tissue and the bone marrow flushed from the distal end using a 25 
gauge needle and 6 mL of ice-cold phosphate-buffered saline (PBS) per femur into 15 mL conical 
tubes. The collected bone marrow was then centrifuged at 4°C for 20 minutes at 100 x g, and 
RNA was subsequently extracted from the cell pellets. Following centrifugation, the cell pellet 
was lysed with STAT-60 (Tel-Test, Inc., Friendswood, TX) according to the manufacturer’s 
directions. Briefly, approximately 1 mL of STAT-60 was added to the cell pellet and resuspended 
by repeated pipetting. After resuspending, the samples were incubated at 25°C for 5 min to allow 
dissociation of ribonucleoprotein complexes. Following the 5 min incubation, 200 µL CHCl3  
(VWR, Catalog #BDH1109-4CG) per mL of STAT-60 used was added to the samples, 
vigorously shaken for 15-20 seconds and then incubated for an additional 2-3 minutes at 25°C. 
Samples were then centrifuged again at 12,000 x g for 15 minutes at 4°C. The aqueous phase 
(containing total RNA) was removed and transferred to a 1.7 mL microfuge tube. Isopropanol 
(#231000099, Pharmco-Aaper, Brookfield CT) was added to the samples (500 µL per 1 mL 
STAT-60 used) and incubated at -80°C for one hour to precipitate RNA. Following precipitation, 
all samples were then centrifuged at 12,000 x g for 10 minutes at 4°C. The RNA pellet was 
washed with 75% ethanol and centrifuged for 5 minutes at 12,000 x g at 4°C. Finally, the pellet 
was briefly dried and then resuspended in diethypyrocarbonate (DEPC)-treated-H2O. RNA 
concentration and purity were determined spectrophotometrically using a Nanodrop-1000 
(Thermo Scientific).  
 The distal metaphysis of the femur was used for RNA extraction from bone tissue, as this 
is metabolically active area is rich in trabecular tissue. To extract RNA from bone, the samples 
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were first homogenized using a freezer mill (6770 Freezer/Mill, Sample Prep, Metuchen, NJ) for 
2 minutes at 12 cycles per second, including a 30 second rest period. Following homogenization, 
by freezer mill, 1 mL STAT-60 per each 100 mg was added to the powdered bone tissue. The 
samples were vortexed, incubated at room temperature for five minutes, and centrifuged for 10 
min at 4°C at 8,000 x g (Eppendorf 5415R). The supernatant was then transferred to a new 1.7 
mL microfuge tube and CHCl3 was added as described above. For precipitation of bone RNA, 
250 µL of a high-salt precipitate solution (0.8 M sodium citrate) was added to the sample in 
addition to 250 µL isopropanol (0.25 mL each, per 1 mL STAT-60 used). The rest of the 
extraction process was carried out using the same methods as bone marrow RNA extraction as 
described above.  
 
Synthesis of cDNA for Gene Expression and Analysis 
 Total RNA was used to synthesize cDNA to examine gene expression by quantitative 
real-time polymerase chain reactions (qPCR, 7900HT Fast Real-time PCR System, SDS 2.3 
Applied Biosystems). Briefly, 2 µg total RNA from each sample first was treated with DNase I 
(Roche Applied Science, Indianapolis, IN) prior to reverse-transcription. Samples were incubated 
at 37°C for 30 minutes and heat inactivated at 75°C for 10 minutes in a thermocycler (BioMetra 
T-Gradient #269980). Following treatment with DNase 1, RNA was reverse-transcribed using 
Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, California). The contents of the 
reverse transcription reaction included 50 mM Tris-HCL pH 8.3, 75 mM KCl, 3 mM MgCl2, 10 
mM dithiothreitol, 10 µM  dioxyribonucleoside triphosphates (2.5 µM each dATP, dCTP, dTTP, 
dGTP) and 0.08 mg/mL random hexamers. The samples were incubated at 25°C for 10 minutes, 
42°C for 50 minutes, and 72°C for 15 minutes in a thermocycler. All samples were stored at -
20°C prior to analysis. 
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Analysis of Gene Expression by Quantitative Real-Time PCR (qPCR) 
 Quantitative real time polymerase chain reactions (qPCR) were used to characterize gene 
expression. Each reaction was performed in triplicate with a final volume of 10 µL per reaction 
that consisted of SYBR Green (SA Biosciences, Frederick, MD), 50 ng cDNA, and 0.3 µM 
primer mix on a 7900HT Fast Real-time PCR System (Applied Biosystems, Foster City, CA). 
Primers were designed using PrimerExpress 2.0 software (Applied Biosystems, Foster City, CA) 
and validated prior to use. Criteria for the validation of primers required that the amplicon 
spanned an intron whenever possible, exhibited a single dissociation curve, and have an 
efficiency slope of -3.3. Primer sequences are described in Table 2. For all gene expression 
analysis, Cylcophilin B was used as the invariant control. All results were analyzed using the 
Comparitive Cycle Threshold Method (CT) (User Manual #2, Applied Biosystems).  
 
Gene Sense Antisense Accession No. 
Cyclo 5’GGTCTTTGGGAAGGTGAAAGAA 5'GCCATTCCTGGACCCAAAA NM_017101 
TfR 5'TCGGCTACCTGGGCTATTGT 5'CCGCCTCTTCCGCTTCA XM_340999 
RPL19 5'CGTCCTCCGCTGTGGTAAA 5'TGGCGATTTCGTTGGTTT NM_031103 
BMP-2 5'GGAAAACTTCCCGACGCTTCT 5'CCTGCATTTGTTCCCGAAAA XM_346016 
Runx2 5'GGCGTCAAACAGCCTCTTCA 5'GCTCGGATCCCAAAAGAAGTT XM_436016  
OCN 5'AATAGACTCCGGCGCTACCT 5'GAGCTCACACACCTCCCTGT NM_013414 
SOST  5’TGAACCGGGCCGAGAAC 5’TGTACTCGGACACGTCTTTGGT NM_030584 
Osx/SP7 5’GCAGCCTGCAGCAAGTTTG 5’CCTTTTCCCAGGGCTGTTG NM_057149 
ALP 5’GCACAACATCAAGGACATCG 5’TGGCCTTCTCATCCAGTTCA NM_013059 
Col1A1 5'AGATTGAGAACATCCGCAGCC 5'TCCAGTACTCTCGCGTCTTCCA NM_053304 
TRAP 5'CAGCCCTTATTACCGTTTGC 5'GAATTGCCACACAGCATCAC NM_019144 
CTSK 5'CTCCATCGACTATCGAAAGAAAGG 5'AGCCCAACAGGAACCACACT NM_031560 
NFATc1 5'TGCAGCTACATGGTTACTTGGAA 5'CGTCAGCCGTCCCAATG XM_001058445 
 
Table 2: Primer pairs used for real-time PCR 
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Protein Assay 
 On the day of necropsy, one tibia was flushed with 3 mL ice-cold Phosphate Buffered 
Solution (PBS) to collect bone marrow cells in 15 mL conical tubes as described above. The 
samples were centrifuged at 800 x g for 5 minutes at 4°C. To prepare cytosolic extracts, the cell 
pellet was resuspended in 200 µL cell lysis buffer (containing 20 mM HEPES, 10 mM sodium 
pyrophosphate, 50 mM β-glycerol phosphate, 50 mM sodium fluoride, 5 mM EDTA, 1 mM 
sodium orthovanadate, and 0.5% v/v NP-40) immediately prior to use, protease inhibitors were 
added to the cell lysis buffer (0.1 mg/mL Pepstatin, 0.1 mg/mL Leupeptin, 0.25 mg/mL Soybean 
Trypsin Inhibitor, 0.1 mM MG132, 0.4 mM phenylmethanesulfonylfluoride), along with 2 mM 
citrate and 1 mM DTT. Following resuspension, the samples were transferred to 1.7 mL 
microfuge tubes, incubated on ice, and vortexed every 5 minutes for 20 min. The samples were 
then centrifuged at 12,000 x g for 15 min at 4°C.  Supernatants were collected, aliquoted, and 
stored in liquid nitrogen. Protein concentration was determined by the BCA assay (Sigma, St. 
Louis, MO).  
 
Electrophoretic Mobility Shift Assay 
 IRP RNA binding activity of cytosolic extracts of bone marrow cells was determined by 
electrophoretic mobility assay. Briefly, a plasmid encoding the rat L-ferritin 5’UTR containing 
the IRE was digested with SmaI prior to the synthesis of radio-labeled RNA as previously 
described [99](Eisenstein RS, 1993, JBC). A 73 nucleotide [32P]-labeled RNA containing the IRE 
was produced by a T7 RNA polymerase. The RNA was gel purified through a 10% 
polyacrylamide/8M urea gel. Following gel purification, the specific radioactivity of the RNA 
protein was determined by scintillation counting. A 4% polyacrylamide gel was prepared using 
30% acrylamide (60:1 acrylamide/bisacrylamide, Amresco # 0172-50G, Solon, OH), MilliPore 
treated water, and 1X Tris/Borate/EDTA buffer (10 mM EDTA, .4 M Boric Acid, .45 M Tris 
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Base). Reaction master mixes were prepared which contained 1 µg cytosolic extract, 5% glycerol, 
1 mmol/L magnesium acetate, 20 mmol/L HEPES, 75 mmol/L potassium chloride, and 20 mg/L 
Bovine Serum Albumin (BSA, Sigma, St. Louis, MO) to a final reaction volume of 30 µL. Total 
IRP1 RNA binding activity was determined by adding 2% βME (Sigma-Aldrich, St. Louis, MO) 
to the reaction and incubating for 20 minutes on ice. Spontaneous binding was analyzed through 
omitting βME. The gel was pre-run at 150V for 20 minutes. After incubation, 3 µL heparin (5 
mg/mL in depc-treated H2O) was added to each sample, and 25 µL from each 33 µL sample was 
loaded onto the gel. The gel was run for an hour at 150V, dried for two hours at 80°C (Bio-Rad 
Model 583 Gel Dryer and HydoTeck Vacuum Pump) and exposed on an imaging screen for 90 
minutes (Bio-Rad Imaging Screen K, Catalog #1707841). The gel was then imaged (Bio-Rad 
Molecular Imager FX, Quantity One 4.4.1 Software) and binding activity quantified using Opti-
Quant Acquisition and Analysis software (Packard Bioscience, Meridien, CA).  
 For quantification, a standard curve of the [32P] radiolabeled RNA was prepared and 
counted using a scintillation counter (Packard Tri-Carb 2900 Liquid Scintillation Analyzer, GMI, 
Inc. Ramsey, MN). The counts per minute (cpm) of the standard curve were then converted to 
digital light units (DLU) and used to calculate the DLUs determined by the phosphoimaged gel. 
Spontaneous binding activity was expressed as fmol RNA bound/mg protein and total RNA 
binding activity was expressed as pmol RNA bound/mg protein.  
 
Statistical Analysis 
 All measurements were statistically analyzed using SAS (Statistical Analysis Software 
version 9.1, Chicago IL). Student’s t-test were performed to find significant differences between 
pair fed and iron deficient animals (p<.05), along with one way analysis of variance (ANOVA) 
between all three groups. However, determination of differences between iron deficient and 
corresponding pair fed groups is a more accurate representation of significant changes due to iron 
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deficiency, as differences in food intake have been controlled in these groups thus, the differences 
that were observed can be confidently denoted as resultant of iron status. 
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CHAPTER IV 
 
 
RESULTS 
 
Dietary iron deficiency is associated with decreased food intake, body weight, organ weight, 
and alterations in body composition. Food intake and weight gain were monitored daily in all 
three dietary treatment groups for the duration of the study. Compared to control animals, the ID 
animals consumed approximately 25% less food (Figure 1A). The cause for this decreased level 
of intake remains unclear, but is consistent with similar models [98, 100]. In agreement with 
decreased intake, the final body weights of the ID animals were 22% lower than control animals 
(Figure 1B). Due to food intake and anthropometric differences between the ID and control 
animals, we included a pair-fed group (PF). The inclusion of a pair-fed group for the iron 
restricted group limited the possibility that the observed differences in iron deficient animals were 
due to a lesser dietary intake. At the end of the 35 day experimental period, both ID and PF 
animals weighed significantly less than the control group (Table 3). Importantly, the difference in 
body weight between ID and PF animals was not significant (Table 3). Both PF and ID animals 
had significantly less fat and lean mass compared to the control animals, accounting for the 
differences in body weight between the groups as determined via DXA scans (Table 3).  Lastly, 
previous studies have indicated that iron deficient animals develop cardiomegaly [13-15].  In the 
current study, significantly higher heart weights were observed in the ID animals (Figure 1C).    
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Iron status of the animals was determined by measuring hemoglobin, hematocrit, and percent 
reticulocytes in the blood. As expected, a dietary iron deficiency was associated with a repression 
in hematocrit and hemoglobin when compared to either C or PF animals (Figure 2). Hemoglobin 
was repressed 66% and hematocrit 61% in iron deficient animals (p<0.0001). To provide further 
evidence of anemia in response to a dietary iron deficiency, we examined the distribution of 
reticulocytes in the blood of the animals. The percent reticulocytes was elevated in iron deficient 
animals (p < 0.0001, Figure 2). The increase in circulating immature red blood cells indicates 
that the animals have an iron-dependent deficit in erythropoiesis.  
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Figure 1: Food intake (A) was significantly reduced (p < 0.01) in ID animals by day 7 when 
compared to control animals. Body weight (B) became significantly different (p < 0.01) on 
day 24 between C and ID/PF animals. Organ weight was normalized to body weight (C) and 
confirmed that ID animals exhibited signs of cardiomegaly (p < 0.05). 
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 Body Weight 
(g) 
Heart Weight 
(g/kg BW) 
Liver Weight 
(g/kg BW) 
Fat Mass (g) Lean Mass (g) 
Control 401.28 ±17.4 7.02 ±0.6 42.41 ±1.2 68.45 ±8.8 332.83 ±9.6 
Pair Fed 316.43 ±5.1* 6.44 ± 0.5 39.18 ±1.2 41.55 ±3.4 274.86 ±3.9 
Iron Deficient 311.48 ±8.1* 7.86 ±0.3** 37.18 ±1.8* 35.50 ± 2.9 276.23 ±6.2 
Table 3: Iron deficient (n=11) and pair fed animals (n=12) weighed significantly less than the 
control group (n=4) after 35 days (p < 0.01 and p < 0.01, respectively). The hearts of the ID 
group weighed significantly more than PF animals (**, p < 0.05) but not control, and the livers 
of ID animals weighed less than control (p < 0.05) but not PF. Values reported as mean ± SE.  
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Figure 2: Hemoglobin (A) and hematocrit (B) were significantly decreased in ID animals 
compared to PF (p < 0.0001), confirming anemia. Percent circulating reticulocytes (C) were 
significant elevated in ID animals (p < 0.0001), providing further evidence of iron deficiency 
anemia. 
  
45 
 
Dietary iron deficiency is associated with increased IRP RNA binding activity of bone marrow 
cells isolated from the femur. Alterations in cellular iron status are sensed by iron regulatory 
proteins. Depletion in cellular iron stores will result in an increase in spontaneous RNA binding 
activity of IRPs. The extent to which iron deficiency alters the iron status of progenitor cells in 
the bone marrow is of interest since these cells give rise to osteoblasts and osteoclasts. In bone 
marrow cells isolated from ID animals, IRP RNA binding activity was increased 2.6-fold when 
compared to PF animals (Figure 3A). Unfortunately, due to the addition of 2 mM citrate to the 
cell lysis buffer used for protein extraction, we were unable to assess total IRP RNA binding 
activity using β-mercaptoethanol and cannot rule out the possibility that changes in IRP RNA 
binding activity are due to an increase in protein abundance rather than a conversion of the 
enzyme form of the protein (i.e., c-aconitase) to an RNA binding form (i.e., IRP1) via the iron-
sulfur cluster switch. To confirm that an increase in IRP RNA binding activity in bone marrow 
cells resulted in the regulation of target mRNAs, we examined the abundance of TfR mRNA. 
Indeed, the 2.6-fold increase in IRP RNA binding activity resulted in an 81% increase in TfR 
mRNA (Figure 3B). Taken together, these results indicate that bone marrow cells are responding 
to a dietary iron deficiency by upregulating the binding activity of IRPs and the subsequent 
stabilization of TfR mRNA in an effort to acquire additional iron from the extracellular 
environment. Although not examined in the current study, it is possible that a repression in bone 
progenitor cell differentiation or proliferation due to a dietary iron deficiency may contribute to 
impaired skeletal health.  
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Figure 3: IRP Binding Activity. In ID animals, spontaneous binding activity in bone 
marrow was significantly increased compared to PF (p < 0.01). Transferrin Receptor 
analysis. As a result of increased IRP RNA binding activity, transferrin receptor (TfR) 
mRNA is stabilized leading to accumulation of TfR mRNA in bone marrow cells of ID 
animals compared to PF animals (p < 0.0001) 
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Iron deficiency negatively alters bone mineral density in the spine and tibia but not of the 
whole body.  Whole-body, spine, and tibia DXA scans were performed to assess the impact of 
dietary iron deficiency on bone mineral area (BMA), content (BMC), and density (BMD). After 
35 days of treatment, there were no differences in whole-body BMA, BMC, or BMD observed 
between the ID and PF animals (Figure 4A-BMA & BMC data not shown).  The tibias and 
lumbar 4/5 (L4/5) were also scanned as these locations are common osteoporotic fracture sites, 
and thus allowed us to examine bone mineral density with a higher degree of sensitivity than that 
obtained by whole body DXA [5]. In agreement with previous studies, the BMA, BMC, and 
BMD at these two sites were significantly decreased in ID animals when compared to PF animals 
(Figure 4A) [14, 15, 26]. Because a decrease in growth or premature closing of the growth plate 
could contribute to a decreased BMA and BMC in the tibia, the lengths of the tibia were 
determined. No differences in tibia length were detected among the three groups, suggesting that 
a severely iron restricted diet did not appear to alter longitudinal bone growth (Figure 4B).  
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Figure 4: No significant alterations in Bone Mineral Density (BMD) were detected 
in the whole body, but the BMD of both the tibia and vertebrae (A) of ID animals 
(n=11) were significantly lower than PF animals (n=12) (p <0.05 and p < 0.0001, 
respectively). There were no differences observed in tibia lengths between the two 
treatment groups (B).  
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Iron deficiency differentially alters skeletal microarchitectural properties of cortical in the tibia 
and trabecular tissue in the lumbar vertebrae. To more closely evaluate the nature of the change 
in BMD, we examined microarchitectural alterations using micro computed tomography (µCT). 
Unexpectedly, no differences were detected between the PF and ID animals in the 
microarchitectural properties of the trabecular-rich metaphyseal region of the proximal tibia 
(Figure 5). Due to the decreased BMD of the tibia in response to iron deficiency, and because 
there were no apparent differences in bone length and structural properties of trabecular tissue, 
we examined the cortical microarchitectural properties of the tibia. Compared to PF animals, ID 
animals exhibited a decreased cortical thickness and an increased medullary area (p < 0.01 
Figure 6). Taken together, these results suggest that decreased BMD in response to a dietary iron 
deficiency is likely associated with alterations in cortical bone properties.   
 In the lumbar spine, a tissue particularly rich in trabecular bone, ID animals exhibited 
significant decreases in bone structural properties. Microarchitectural analysis revealed that 
BV/TV, TbN, TbTh, and TbSp were all decreased in ID animals (Figure 7A-D). Furthermore, the 
connectivity density of the tissue, an indicator of the overall density of the connections between 
trabeculae, was significantly lower in the lumbar vertebrae of ID animals (Figure 7E). Lastly, the 
structural model index (SMI) was elevated in ID animals, indicating a more rod-like trabeculae 
characteristic that is associated with an enhanced  fracture risk (Figure 7F). 
 To further examine structural properties of the bone, finite element analysis (FEA) was 
performed using a computer-simulated model. Since FEA assessed trabecular tissue, it was not 
surprising that FEA did not reveal any differences between ID and PF animals (data not shown), 
despite changes in BMD and cortical microarchitecture of the tibia. However, FEA of L4 
vertebrae indicated significantly weaker bones in ID animals. Both stiffness (Figure 8A) and size 
independent stiffness (Figure 8B) were significantly less in ID animals (p < 0.01), and 
physiological force (Figure 8C) estimated to break the bone was also significantly decreased (p < 
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0.01). The Von Mises stress criterion value was not significantly different in ID compared to PF 
animals, but trended towards being higher. Depictions of the tibial midshaft and L4 can be 
observed in Figure 9.  
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Figure 5: Trabecular µCT analysis of the proximal tibial metaphysis.  No significant 
differences were observed in microarchitectural properties of the trabecular tissue between 
PF and ID animals. 
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Figure 6: Cortical µCT analysis of the tibia. Cortical thickness (A) was significantly 
lower in ID animals (p < 0.05). There were no differences in porosity (B) or cortical area 
(C).Consistent with a decrease in cortical thickness, cortical medullary area (D) was 
increased in response to a dietary iron deficiency (p < 0.05). 
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Figure 7: Trabecular µCT analysis of Lumbar 4 (L4) Vertebrae. BV/TV (A), TbN (B), and 
TbTh (C) were all significantly lower among ID animals (p < 0.001). TbSp (D) was 
significantly higher in ID animals (p < 0.001) .Connectivity density (E) was less in ID 
animals (p < 0.0001). SMI was significantly higher (p < 0.001) in ID animals.  
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Figure 8: Finite element analysis (FE) of vertebral body (Lumbar 4). Stiffness 
(A), size independent stiffness (B), and total force (C) are all significantly 
reduced in ID animals (p < .01). Von Mises stress (D), the maximum force a 
bone can withstand before yielding, trends towards being higher than PF, but this 
was not significant.   
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  Figure 9: Micro-computed tomography images of the tibia cortical tissue (A-B) and 
vertebral trabecular tissue (C-D). Iron deficient animals exhibited lesser cortical 
thickness combined with a greater medullary area (B), and vertebral bodies with lesser 
trabecular volume, thinner, fewer, and further spaced trabeculae resulting in a lower 
connectivity density (D).  
A 
D C 
B 
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Expression of bone related genes in femur. To further investigate the nature of the 
microarchitectural alterations observed in iron deficient animals, gene expression in a trabecular-
rich region of the femur was examined. These analyses were conducted on femurs whose marrow 
cavity had been flushed to remove bone marrow cells. Total RNA was then extracted from the 
distal metaphysis of the bone and used as a template for the synthesis of cDNA for gene 
expression analyses by qPCR. The osteogenic genes osteocalcin (OCN), bone morphogenetic 
protein-2 (BMP-2), and collagen1A1 (COL1A1) were all significantly reduced in ID animals 
(Figure 10A), suggesting that this tissue may be experiencing an impairment in mineralization in 
response to a dietary iron deficiency. Although the expression of the gene encoding the protein 
alkaline phosphatase trended towards being reduced, the decrease in expression was not 
statistically significant.  Next, to further examine the nature of alterations in osteogenic gene 
expression, the expression of key transcriptional regulators of osteoblastic differentiation were 
examined.  The expression of Runx2, a transcription factor that regulates the expression of the 
transcription factor osterix/SP7, was significantly repressed in response to iron deficiency 
(Figure 10B).  In agreement with a repression in Runx2, the expression of osterix/SP7 was also 
significantly impaired (Figure 10B).  Taken together, these results suggest that an impairment in 
the differentiation or total number of osteoblasts in ID animals may, in part, contribute to the 
microarchitectural abnormalities observed in iron deficiency. 
To further investigate factors contributing to iron-dependent alterations in bone 
microarchitecture, the expression of genes involved in osteoclast function were examined. 
Cathepsin K (CTSK), nuclear factor of activated T-cells, calcineurin dependent (NFATc1), and 
tartrate resistant acid phosphatase (TRAP) did not significantly change in ID animals compared to 
PF, indicating that the primary effect of iron deficiency is likely in osteoblasts, and that any 
change in osteoclast mRNA expression is reflective of a lesser mature osteoblast population.   
Figure 10: The expression of genes involved in supporting bone mineralization 
was analyzed using quantitative real-time PCR (qPCR).  Total RNA was extracted 
from the metaphyseal region of the femur and used to synthesize cDNA.  Relative 
differences in target gene expression of alkaline phosphatase (ALP), osteocalcin 
(OCN), bone morphogenetic protein-2 (BMP-2), collagen1α1 (COL1A1), Runx2, 
and osterix (SP7) were determined by qPCR utilizing SYBR Green chemistry and 
normalized to the expression of RPL19 (mean CT=20.3).  Numbers in parentheses 
indicate the mean CT value for the PF animals. Overall, the expression of these 
genes was lower in ID animals (p < 0.01).  
  
58 
 
  
Figure 1: The expression of osteoprotegerin (OPG) and RANKL in cDNA 
from the metaphyseal region of the femur was normalized to RPL19 (Mean 
CT= 20.5). No statistically significant differences were detected in either, but 
both genes exhibited trends toward decreased expression.  
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Figure 12: The expression of osteoclast related genes. Cathepsin K (CTSK), 
nuclear factor of activated T-cells calcineurin dependent (NFATc1), and 
tartrate resistant acid phosphastase (TRAP) were examined in femur cDNA 
samples. No significant differences were detected between ID and PF. Values 
in parenthesis indicate the mean CT value of PF animals. Genes were 
normalized to RPL19 (mean CT=21.1). 
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CHAPTER V 
 
 
DISCUSSION 
 
 Iron is an essential nutrient responsible for a myriad of functions in the human body, 
including oxygen transport, nutrient metabolism, and cell proliferation [3]. Enzymes requiring 
iron as a co-factor such as prolyl hydroxylase (collagen crosslinking), aconitase, and 
ribonucleotide reductase (DNA synthesis) make iron a crucial micronutrient for normal cell 
growth, proliferation, and the maintenance [17]. During periods of growth, iron requirements are 
elevated to support cell proliferation and increased metabolic needs, yet iron deficiency anemia 
continues to affect an estimated 9-16% of females of childbearing age (approximately 12-49) in 
the United States [3, 20]. Nutrient deficiencies during periods of growth are of particular concern 
due to the negative implications nutrient deficits can have on development.  More specifically, a 
lack of adequate iron in growing children may contribute to impaired cognition, decreased energy 
production, and interestingly, perhaps even lower bone mineral density (BMD) and weaker bone 
microarchitecture [3, 14, 26]. Several studies utilizing animal models of iron deficiency have 
demonstrated a link between an impaired iron status and lower bone mineral density (BMD), 
although the molecular mechanisms responsible for the relationship between iron status and bone 
health remain unclear [13-15, 27].  It is speculated that iron-containing enzymes involved in bone 
formation and mineralization such as prolyl hydroxylase may partially explain the negative effect 
of iron deficiency on BMD [13, 14, 30].  In fact, the recent observations that iron deficiency 
anemia is correlated with an increased risk of stress fracture provides further evidence that iron 
status may contribute to an increased risk of osteoporosis [27]. Furthermore, iron overload 
disorders (e.g., hemochromatosis) are associated with a decrease in BMD, suggesting that iron 
status plays an important role in the regulation of normal bone metabolism [16, 27].  In an animal 
model of iron deficiency, serum 1,25-dihydroxycholecalciferol and urinary deoxypyridinoline 
(DPD) excretion, a measure of bone resorption, were both decreased  [15]. These findings of 
decreased resorption biomarkers coupled with negatively altered histomorphometric results 
provide further evidence that severe iron deficiency results in impaired bone formation, and may 
explain decreases in BMD [15]. However, the mechanism(s) through which iron status alters 
bone formation remains to be determined. 
 In this present study, we have demonstrated that a profound iron deficiency in a 
developing animal was associated with significant negative alterations in bone microarchitecture. 
In fact, iron status appeared to not only affect regions rich in trabecular bone, but also cortical 
bone, though there did appear to be some site-specific responses.  For example, although the 
trabecular region of the tibia was unaffected by iron status, the trabecular bone of the lumbar 
vertebrae was significantly impaired in response to iron deficiency.  To begin to understand the 
possible mechanisms contributing to this relationship, we took a biased approach of examining 
the expression of genes involved in osteoblast and/or osteoclast differentiation and function. By 
primarily focusing on the functionality of osteoblasts, a stronger argument can be made that iron 
deficiency has a profound effect on the activity of these cells. Although osteoblast-related gene 
expression was decreased, we are not able to rule out the possibility that this was an indirect 
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effect of an impaired iron status on the differentiation of pre-osteoblasts to mature mineralizing 
osteoblasts. The expression of key transcriptional regulators of osteoblast differentiation (i.e., 
Runx2 and Osx/SP7) was decreased in response to iron deficiency.  These results suggest that 
lack of adequate iron may impair the differentiation of osteoblasts resulting in an overall decrease 
in the number of osteoblasts. The reduced expression of genes encoding the osteoblast secretory 
proteins osteocalcin (OCN) and collagen type 1a1 (COL1A1) in iron deficient animals may 
contribute to impaired mineralization.  This proposed mineralization defect may partially explain 
alterations in BMD observed in the current study.   
Taken together, these results indicate that iron deficiency is likely associated with an 
impairment of mesenchymal stem cell differentiation to mature osteoblasts. As Runx2 is thought 
of as the ‘master regulator’ of osteoblast-directed MSC differentiation, it is important to consider 
and further explore the factors that would explain the down-regulation of Runx2; namely, the 
signaling pathways such as Wnt/β-catenin, bone morphogenetic proteins as part of the 
transforming growth factor-β superfamily (TGFβ), and SMADs [37, 38].  Iron and heme are 
capable of inducing Wnt signaling, but it is unknown how a lack of iron affects Wnt signaling 
[101]. Given that previous work regarding iron and Wnt signaling has been conducted in 
carcinoma cell lines to look at the induction of oncogenes from Wnt/β-catenin signaling, it is not 
very feasible to apply the findings of these studies to our current work [101].  However, it does 
indicate that iron is in some way connected to the Wnt signaling pathway, and should be an 
important focus for future research. In mice, iron deficiency has been shown to decrease 
phosphorylation, and therefore activation, of Smad 1/5/8, which would presumably then decrease 
further differentiation of MSCs to osteoblasts [84]. The connections between BMP-2, Smad, and 
Wnt/β-catenin signaling and iron status are only in the beginning stages of characterization, and 
may be an important means of determining the connection between iron and bone metabolism.  
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In the present study, we found that the expression of BMP-2 was significantly decreased 
in iron deficient animals. BMP-2 is associated with stimulation of osteoblastic gene expression 
including OCN and COL1A1. Additionally, BMP-2 regulates Osx/SP7 through modulating both 
Runx2 and Msx2, a homeobox gene. Thus, BMP-2 likely plays an important role in the regulation 
of differentiation of osteoblasts from MSCs [33, 102]. Intriguingly, that others have demonstrated 
the involvement of both BMP-2 and BMP-6 in mediating the expression of the peptide hormone 
hepcidin as part of systemic iron regulation raises interesting questions [78, 79]. First, given that 
the expression of BMP-2 and -6 are acutely regulated in response to elevated iron stores, are these 
proteins also negatively regulated in response to iron deficiency? Second, how might iron be 
involved in the regulation of these key signaling proteins? Although we did not measure the 
abundance of BMP-2 protein, our results indicating a repression of BMP-2 gene expression may 
provide a key connection between cellular iron status and bone metabolism.  The results of the 
present study suggest that an impaired iron status may adversely affect the osteoblast 
differentiation pathways resulting in fewer or less active osteoblasts which could result in 
mineralization defects. It is possible that iron deficiency lowers the overall population of stem 
cells, or that any available iron is being utilized for hematopoietic stem cell differentiation into an 
erythrocyte lineage, thereby decreasing mesenchymal stem cell proliferation and differentiation.  
Under normal conditions, osteoblasts induce osteoclast maturation and activation through 
the secretion of RANK and M-CSF. Thus, it is possible that the decreased population of mature 
osteoblasts is at least partially responsible for the observed downregulation of osteoclast-
associated genes such as the transcription factor NFATc1, TRAP, and CTSK. These results may 
provide a mechanistic basis for the previous finding that iron deficiency results in a fewer bone 
resorbing osteoclasts [15]. Therefore, though it appears that the numbers of both mature 
osteoblasts and osteoclasts are decreased, the rate of bone formation appears to be insufficient to 
overcome the relative difference in bone resorption.  In some ways these results are surprising 
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since osteoclast differentiation is somewhat dependent upon the balance of RANKL and OPG 
secretion.  The nature of the iron-dependent alterations in osteoblast and osteoclast differentiation 
remains to be determined.  
 The BMD of the spine and tibia was significantly decreased in ID animals. A further 
examination by microcomputed tomography (µCT) at the distal metaphysis of the tibia did not 
reveal apparent differences in bone volume, trabecular thickness, or trabecular number that could 
explain the significant alterations observed by DXA analysis. However, the cortical tissue at the 
midshaft of the tibia was significantly thinner in iron deficient animals, with a commensurate 
increase in medullary area which may provide some insight to the nature of the difference in 
BMD detected using DXA. Although we were not able to examine the gene expression in tissue 
that was analyzed by DXA or µCT, our results are consistent with a role of iron modulating 
osteoblastic and/or osteoclastic differentiation or function thereby resulting in structural changes 
in the bone.  
 Future studies are needed to more quantitatively identify the impact of iron deficiency on 
the cell differentiation to determine the extent to which the negative consequences of impaired 
iron status are due to a direct effect on the total cell populations of osteoblasts and osteoclasts.  
The nature of the site-specific responses (e.g., tibia versus vertebrae) remains unclear, but is not 
uncommon.  That the trabecular bone in the tibia appears to be unaffected by iron status over 35 
days is interesting given the apparent sensitivity of the tissue of the spine.  To the best of our 
knowledge, we are unaware of other studies that have examined both the cortical and trabecular 
tissue of tibias in ID animals.  Another group has demonstrated that the cortical thickness of the 
femur midshaft is decreased in animals with an impaired iron status [26]. In the same study, 
Parelman et al indicate that simulated iron deficiency in an immortalized human osteoblast cell 
line led to a defect in mineralization but not in collagen synthesis [26]. The reason for this 
‘selective’ action on cortical but not trabecular tissue in long bones is not understood, because 
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trabecular tissue in the spine has been repeatedly shown to undergo negative alterations as a result 
of iron deficiency [14, 26]. Nevertheless, the microarchitectural alterations in both tibia and spine 
in the present study were significant enough to induce a decrease in BMD in both sites, which is 
typically considered a less sensitive measure of bone density when compared to µCT, as it details 
the manner by which the alterations are taking place.  
 One of the major caveats in this study was the fact that although µCT and DXA scans 
were performed on tibias and the 4th lumbar, qPCR expression analysis was carried out in samples 
from the distal metaphysis of the femur. Ongoing work on a current study is being carried out to 
A second limitation to this study is that cell lineage allocations of the bone marrow cells were 
unknown. Thus, we are unable to determine whether overall cell population is decreased in an 
iron deficient animal, or whether the population of stem cells favors hematopoietic over 
mesenchymal or vice versa.  Several possibilities to amend this problem are flow cytometry or 
analysis of differentials in the blood. However, flow cytometry on rat samples is challenging, due 
to the lack of well-characterized antibodies for rat species. This would likely impede our ability to 
determine the cell population we were actually working with. Differential counts in the blood 
would be beneficial in regards to estimating whether the stem cell types present in the bone 
marrow were more heavily weighted towards hematopoietic versus mesenchymal or vice versa, 
but would still not provide information on the size of the stem cell population. As previously 
discussed, it is certainly a possibility that overall stem cell population is decreased as a result of 
inadequate dietary iron. These questions were not answered in the current study, but are important 
to consider for further investigation.  
 Additionally, the difference in strains of rats used across the studies may be considered a 
limitation to our work. Studies done by Medeiros and Parleman et al were conducted in Long-
Evans rats, Katsumata et al used a Wistar rat model, and in our present study we chose to use 
Sprague-Dawley rats [13-15, 26]. Not surprisingly, different strains of rats have been shown to 
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react in different ways to alterations in iron status [103]. In a comparison study of iron deficiency 
(ID) in Fischer, Wistar, and Sprague Dawley rats, it was determined that Fischer rats were the 
most susceptible to ID, followed by Wistar and finally Sprague Dawley [103]. This determination 
was based on hemoglobin and serum iron levels after the animals had been fed a diet that 
contained < 10 ppm Fe [103]. Thus, our use of SD rats may be a source of controversy for this 
particular topic. For example, if SD rats are a difficult strain to induce a state of iron deficiency, 
our findings of reduced BMD and bone microarchitecture may not be as profound as the 
alterations in other strains. Nevertheless, our results of significantly altered BMD and 
microarchitecture indicate that our level of iron-restriction was sufficient for the purposes of 
examining the alterations in bone. 
 However, the differing levels of iron in the diets used across the different studies must 
also be considered, as each of these studies utilized different iron concentrations. We chose a 
level of 2-5 mg Fe/kg as our iron-restricted diet so as to evaluate skeletal alterations in a severely 
iron deficient model; this was likely a more reasonable range of iron restriction to use based on 
the potential challenges in inducing iron deficiency in SD rats [103]. Parelman indicates that a 
level of 12 mg Fe/kg significantly decreased L4 trabecular number and increased trabecular 
separation, but did not affect trabecular thickness [26]. Again, this may be due to strain 
differences, but to date no studies have been conducted comparing Long Evans rats with Sprague 
Dawley. However, cortical thickness in the femur was significantly decreased in Parelman’s 
work, consistent with our findings [26]. Medeiros et al utilized a level of 5-8 mg Fe/kg for both 
studies, and reported significant skeletal alterations consistent with that of our study and 
Parelman’s [13, 14]. This indicates that even a moderate level of iron deficiency can cause 
negative alterations in skeletal microarchitecture, thereby re-enforcing the importance of adequate 
dietary iron, especially during times of growth and development.  
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 In conclusion, the results of the study presented herein indicate that a relatively severe 
dietary iron deficiency negatively affects skeletal health and reinforces the need to further 
characterize the role of iron in maintaining optimal bone health.  This remains an important issue 
due to the prevalence of iron deficiency, especially among a population that is also undergoing 
rapid development and the accretion of peak bone mass.  Evidence is now emerging that suggests 
iron status may be an important risk factor for the development of chronic diseases such as 
osteoporosis.  The results from this study suggest that iron status may affect the cellular 
differentiation and proliferation of cells responsible for bone formation.  It remains to be 
determined as to the extent to which alterations in bone structure can be reversed by improving 
iron status.  Nonetheless, as a result of iron deficiency, it appears that osteogenic gene expression 
is reduced and may partially explain the microarchitectural alterations observed in both the tibia 
and the spine. 
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mechanism by which this occurs. Weanling Sprague Dawley rats were assigned to 
one of three dietary treatments for 35 days: severe iron restriction (< 3 mg Fe/kg 
diet), control (50 mg Fe/kg diet), or pair-fed control diet to the level of intake of 
the iron restricted animals. Analysis of bone mineral density (BMD) and 
microarchitecture were obtained by DXA and microcomputed tomography (µCT) 
in both the tibia and spine. RNA was extracted from the femur and used to 
synthesize cDNA for quantitative real-time polymerase chain reactions (qPCR).  
 
 
Findings and Conclusions:  Iron deficiency was confirmed by the expression of 
transferrin receptor mRNA in bone marrow cells (3.6-fold higher in iron-
restricted animals, p<0.05). BMD (-12%) and bone microarchitecture of spines 
from animals receiving both levels of iron restriction were decreased (p<0.05), 
whereas no changes were observed in the tibia. Trabecular number and thickness 
were significantly decreased (p<0.001) coupled with an increase in trabecular 
separation in the spine.  mRNA expression analysis revealed significant down-
regulation of key osteogenic factors including Runx2, osterix, and bone 
morphogenetic protein-2 (BMP-2). Our findings indicate that iron deficiency 
negatively impact the differentiation and maturation of mesenchymal stem cells 
into osteoblasts, based on the observed decrease in expression of BMP-2, Runx2, 
and osterix. Thus, our results demonstrate that severe iron deficiency during a 
period of rapid growth is very likely a risk factor for osteoporosis, and that future 
research regarding the mechanism by which this occurs is warranted.  
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